Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Culture adapted T. b. gambiense isolated from Northwest Uganda were exposed to 0.001-0.14 microg/ml melarsoprol or 1.56-100 microg/ml DL-alpha-difluoromethylornithine (DFMO). Minimum inhibitory concentrations (MICs) of each drug were scored for each isolate after a period of 10 days drug exposure. The results indicate that T. b. gambiense isolates from Northwest Uganda had elevated MIC values for melarsoprol ranging from 0.009 to 0.072 microg/ml as compared with T. b. gambiense isolates from Cote d'Ivoire with MIC values ranging from 0.001 to 0.018 microg/ml or with T. b. rhodesiense from Southeast Uganda with MIC values from 0.001 to 0.009 microg/ml. All MIC values obtained fell below expected peak melarsoprol concentrations in serum of treated patients. However, it may not be possible to maintain constant drug concentrations in serum of patients as was the case in our in vitro experiments. Importantly, the MIC of 0.072 microg/ml exhibited by one of the isolates from Northwest Uganda was above levels attainable in CSF indicating that this isolate would probably not be eliminated from CSF of treated patients. PCR amplification of the gene encoding the P2-like adenosine transporter followed by restriction digestion with Sfa NI enzyme revealed presence of fragments previously observed in a trypanosome clone with laboratory-induced arsenic resistance. From our findings it appears that reduced drug susceptibility may be one factor for the frequent relapses of sleeping sickness after melarsoprol treatment occurring in Northwest Uganda.
Matovu
E
E
Livestock Health Research Institute, Tororo, Uganda.
Enyaru
J C
JC
Legros
D
D
Schmid
C
C
Seebeck
T
T
Kaminsky
R
R
D000818:Animals; D016054:DNA, Protozoan / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D000518:Eflornithine / Q000627:therapeutic use; D006801:Humans; D008549:Melarsoprol / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012008:Recurrence; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014347:Trypanosoma brucei gambiense / Q000187:drug effects* / Q000235:genetics; D014353:Trypanosomiasis, African / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology*; D014454:Uganda / Q000453:epidemiology
D016054:DNA, Protozoan; D014344:Trypanocidal Agents; D008549:Melarsoprol; D000518:Eflornithine